Montreal, QC – July 1, 2025 – MY01, an innovative medical technology company focused on transforming the diagnosis of limb perfusion injuries, is excited to announce the official commercial launch of its Continuous Perfusion Sensing Technology (CPST) Platform®.

The CPST Platform®, designed around MY01’s breakthrough MEMS Sensor technology, includes the MY01 Base Station, a fully integrated, plug-and-play system designed to guarantee maximum clinical value. This system ensures that clinical teams can seamlessly incorporate perfusion data through secure connectivity into their existing workflows. With this launch, MY01 is changing how hospitals monitor and respond to potential limb perfusion injuries—one of the most critical and time-sensitive challenges in trauma care.

“This launch represents more than just a new product; it signifies a paradigm shift in trauma care,” said Andrew Morris, Chief Commercial Officer at MY01. “The CPST Platform provides frontline teams with consistent, reliable real-time data, enabling them to make earlier and more accurate diagnoses. When complications can be recognized quickly and with certainty, care teams can optimize patient care with confidence.”

By making continuous perfusion monitoring intuitive and accessible, MY01 is helping hospitals reduce variability in care, enhance clinical outcomes, and optimize resource utilization.

About MY01
Founded in 2019 and based in Montreal, MY01 envisions a world where every disease is quantifiable, allowing for precise, personalized care for all patients. Our Continuous Perfusion Sensing Technology (CPST) Platform has the potential to transform trauma programs by translating complex biological signs into dynamic, actionable, real-time data that supports better decision-making. This reduces variations in care and delivers improved outcomes, enabling hospitals to allocate resources as efficiently as possible. MY01 is currently operational in the USA, Europe, and Canada, setting new standards in healthcare.